Olaparib has solidified its place as a standard maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer who have BRCA mutations. In the phase III SOLO 2 trial, the drug extended overall survival by more than a year in these patients compared with a placebo.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.